0001601364-15-000001.txt : 20150126
0001601364-15-000001.hdr.sgml : 20150126
20150126165959
ACCESSION NUMBER: 0001601364-15-000001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150122
FILED AS OF DATE: 20150126
DATE AS OF CHANGE: 20150126
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Versartis, Inc.
CENTRAL INDEX KEY: 0001513818
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 244106690
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4200 BOHANNON DRIVE
STREET 2: SUITE 250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 6509638580
MAIL ADDRESS:
STREET 1: 4200 BOHANNON DRIVE
STREET 2: SUITE 250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Advent Life Sciences Fund I LP
CENTRAL INDEX KEY: 0001601363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36361
FILM NUMBER: 15549185
BUSINESS ADDRESS:
STREET 1: 158 NORTH GOWER STREET
CITY: LONDON
STATE: X0
ZIP: NW1 2ND
BUSINESS PHONE: 44 (0) 207 932 2120
MAIL ADDRESS:
STREET 1: 158 NORTH GOWER STREET
CITY: LONDON
STATE: X0
ZIP: NW1 2ND
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Advent Life Sciences LLP
CENTRAL INDEX KEY: 0001601364
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36361
FILM NUMBER: 15549186
BUSINESS ADDRESS:
STREET 1: 158 NORTH GOWER STREET
CITY: LONDON
STATE: X0
ZIP: NW1 2ND
BUSINESS PHONE: 44 (0) 207 932 2120
MAIL ADDRESS:
STREET 1: 158 NORTH GOWER STREET
CITY: LONDON
STATE: X0
ZIP: NW1 2ND
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2015-01-22
0
0001513818
Versartis, Inc.
VSAR
0001601364
Advent Life Sciences LLP
158 NORTH GOWER STREET
LONDON
X0
NW1 2ND
UNITED KINGDOM
0
0
0
1
Affiliate of Director
0001601363
Advent Life Sciences Fund I LP
158 NORTH GOWER STREET
LONDON
X0
NW1 2ND
UNITED KINGDOM
0
0
0
1
Affiliate of Director
Common Stock
2015-01-22
4
P
0
55000
17.25
A
2271558
I
See FN
Option (Right to Buy)
21
2014-03-19
Common Stock
35000
35000
I
See FN
Securities are held by Advent Life Sciences LLP ("Advent") and Advent Life Sciences Fund I LP ("Advent Fund"). Advent is the general partner of Advent Fund. Advent disclaims beneficial ownership of the shares held by Advent Fund except to the extent of its indirect pecuniary interest therein. Shahzad Malik, an affiliate of the Reporting Persons, is a member of the Issuer's board of directors, and disclaims beneficial ownership of the shares held by Advent or the Advent Fund except to the extent of his indirect pecuniary interest therein.
One-fourth of the total number of shares subject to the option shall vest and become exercisable one year from 3/21/2014 (the "Vesting Commencement Date") and 1/36th of the remaining number of shares subject to the option shall vest and become exercisable on each monthly anniversary of the Vesting Commencement Date thereafter.
Securities are held by Shahzad Malik, an affiliate of the Reporting Persons. The Reporting Persons disclaim beneficial ownership of the securities held by Shahzad Malik.
The Reporting Persons are no longer greater than 10% holders. Shahzad Malik, an affiliate of the Reporting Persons, is a member of the Issuer's board of directors.
/s/ Shahzad Malik, General Partner, Advent Life Sciences LLP
2015-01-26
/s/ Shahzad Malik, General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund I LP
2015-01-26